Physician profile
David Webner
NPI 1306874441
$12,191.75
in general payments reported to CMS, 2019-2025
13 companies · $579 in 2025
The $579 reported for 2025 was more than what 84% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,615 · 2020: $3,942 · 2021: $45.60 · 2023: $126 · 2024: $885 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Travel and Lodging: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.68 |
| Travel and Lodging | $601.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $8,727.29 | 2019-2020 | |
| Bioventus LLC | $1,177.75 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $748.39 | 2023-2025 | Iovera, Zilretta |
| Pacira Therapeutics, INC. | $384.04 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $371.89 | 2024-2025 | Strensiq |
| Zimmer Biomet Holdings, INC. | $198.30 | 2023-2025 | Gel-One Cross-Linked Hyaluronate |
| Fidia Pharma USA INC. | $161.74 | 2019-2020 | |
| Depuy Synthes Sales INC. | $148.28 | 2019-2025 | Monovisc, Orthovisc |
| Hydrocision, INC. | $143.90 | 2025 | Tenjet |
| Ferring Pharmaceuticals INC. | $58.21 | 2019-2020 | |
| Kyowa Kirin, INC. | $29.39 | 2024 | Crysvita |
| Synergy Orthopedics, LLC | $24.15 | 2019 | |
| Qiagen, LLC | $18.42 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Webner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.